Skip to main content

Table 2 Efficacy outcome measures

From: Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: an open-label study

Outcome measure

Mean baseline score

Mean change (SE)

  

Week 6

Week 28

Week 52

CGI-Severity

4.51

-2.08 (0.11)**

-2.93 (0.12)**

-3.15 (0.12)**

PGI-Improvement

N/A

2.33 (0.14)**

1.83 (0.16)**

1.84 (0.16)**

HAMD 17 Total Score

21.8

-13.0 (0.7)**

-17.4 (0.8)**

-17.5 (0.8)**

   Anxiety subscale

6.70

-3.46 (0.30)**

-4.89 (0.33)**

-4.90 (0.34)**

   Core subscale

8.83

-5.65 (0.33)**

-7.50 (0.36)**

-7.61 (0.38)**

   Maier subscale

10.7

-6.64 (0.38)**

-8.90 (0.42)**

-9.06 (0.44)**

   Retardation subscale

7.84

-4.49 (0.27)**

-6.58 (0.30)**

-6.49 (0.31)**

   Sleep subscale

3.68

-2.34 (0.21)**

-2.84 (0.23)**

-2.83 (0.24)**

   HAMD17 Item 1

2.64

-1.73 (0.11)**

-2.30 (0.13)**

-2.30 (0.13)**

   HAMD17 Item 3

0.74

-0.58 (0.06)**

-0.59 (0.06)**

-0.61 (0.06)**

BDI-II Total Score

29.5

-15.8 (1.0)**

-22.3 (1.1)**

-22.0 (1.1)**

Sheehan Disability Scale

    

   Work item

6.91

-3.01 (0.32)**

-4.60 (0.37)**

-4.27 (0.39)**

   Family item

6.82

-3.63 (0.32)**

-4.88 (0.35)**

-4.95 (0.37)**

   Social item

7.27

-3.45 (0.34)**

-4.57 (0.38)**

-4.85 (0.40)**

  1. ** p < .001 from t-test for mean change
  2. CGI-Severity = Clinical Global Impression of Severity; PGI-Improvement = Patient Global Impression of Improvement; HAMD17 = 17-item Hamilton Rating Scale for Depression; BDI-II = Beck Depression Inventory-II